Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
A. Calmy, Tamara Tovar Sanchez, C. Kouanfack, Mireille Mpoudi-Etame +76 more

